Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

Massachusetts' largest commercial health insurer is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

The drugmaker Eli Lilly this week said that tests of its GLP-1 pill could work just as well as injectable drugs like ...